Understanding continuous bioprocessing: Discover the benefits of predictive maintenance, machine learning and advanced process control
The UK is currently on the cusp of a Fourth Industrial Revolution, and integration of industrial digital technologies (IDTs) into manufacturing is key to fully realise economic benefits available to manufacturing and UK PLC. As biopharma matures, the industry will increasingly need to find ways to maintain competitiveness by ensuring affordability and quality. IDTs developed will be immediately applicable to bioprocessing to realise cost savings in biotherapeutic manufacturing, facilitating the adoption of continuous manufacturing in the high value biologics sector, while creating an IDT toolkit to support modular manufacturing across multiple sectors, whether batch or continuous.
In this webinar we will discuss two case studies using predictive & prescriptive maintenance, machine learning and advanced process control approaches for continuous bioprocessing to improve manufacturing, reduce process development timelines and costs associated with drug development and manufacture.
- Industry challenges around process control and an overview of the output from projects aimed at overcoming these challenges
- Impact of predictive and prescriptive maintenance through the exemplification of specific unit operations (filtration/chromatography)
- The value of machine learning and advanced process control approaches to control pH and DO in bioprocesses
- Question and answer session
Dr Asif Tulah, CPI
Dr Asif Tulah is a Business Development Manager for CPI focusing on the Biologics capabilities housed in the National Biologics Manufacturing Centre in Darlington, UK. Asif joined CPI in July 2020 and has experience of international business development and sales, previously leading the business development activities for an SME. He has experience developing solutions to clients in the pharmaceutical, cosmetic and chemical industries, particularly the US, Europe and Asia. His research experience involved working between industry and academic institutions on innovation projects helping to bring new technologies to the market. This included working as a Product Development Scientist in beauty and healthcare and as an R&D Scientist working on projects related to drug discovery, safety and efficacy. Asif has a PhD in Molecular Medicine from the University of Nottingham.
Dr. Sean Ruane Downstream Development Scientist at CPI’s National Biologics Manufacturing Centre in Darlington, UK.
Sean joined CPI in October 2020, taking a role as CPI’s technical lead for the EU-funded AMECRYS project. Sean is also involved in several other downstream projects, with a focus on continuous production, digital integration and PATs. Sean obtained a PhD in Biological Physics at the University of Manchester (co-sponsored by AstraZeneca), in which he investigated protein adsorption at oil/water interfaces, using neutron reflection and probabilistic modelling to determine the conformation of adsorbed monoclonal antibodies.
Mr. Jonathan Jones, Team Leader in Upstream Processing at CPI’s National Biologics Manufacturing Centre in Darlington, UK.
An experienced Upstream scientist with a focus on the process development and scale-up of bioprocesses across a range of cell types and products. Jonathan is familiar with high-throughput upstream process development, design of experiment approaches to process optimisation and process scale up and validation. At CPI Biologics, Jonathan is a team leader within the upstream team, working across mammalian, microbial, and cell free projects, with a passion for tackling digital challenges within bioprocessing.
Mr. Ben Gay, Degree Level Apprentice at CPI’s National Biologics Manufacturing Centre in Darlington, UK.
Laboratory Technician within CPI Biologics, with 4.5 years’ experience in method development and scale up of downstream processes for a range of biopharmaceuticals including recombinant proteins, viral vectors, and mRNA. He is currently completing his BSc (Hons) in Biological Sciences from Teesside University.
Mr John Mack, Perceptive Engineering Limited
John is the Perceptive Engineering business unit head within Applied Materials, leading the team delivering software and solutions for APC, process monitoring and optimisation across process industries. He has 22 years’ experience developing novel applications for continuous pharmaceutical processes through to lab-scale crystallisers and micro-fluidic systems. John is a Chartered Engineer with a BEng/NZCE from Auckland University.
Dr Eduardo Lopez Montero, Perceptive Engineering Limited
Eduardo is a Senior Engineering Consultant in Perceptive Engineering. He has a PhD from the University of Manchester’s Control Systems Research Group in the application of multivariate statistical methods for control of chemical batch processes. Eduardo’s role is to deliver Advanced Process Control and optimisation systems in the pharmaceutical and biopharmaceutical industries.
Dr Tibor Nagy, Director, Bioprocess Strategy and Development, FUJIFILM Diosynth Biotechnologies.
Tibor Nagy is Director of the Bioprocessing Strategy and Development group at FUJIFILM Diosynth Biotechnologies (FDB) leading the development of downstream processes for manufacturing clinical and commercial biologics. He joined the process development team at FDB’s Billingham, UK site in 2007 as Technical Project Leader and became the site technical expert in several areas including bioinformatics. He developed a proprietary bioinformatics workflow which is used to support early stage process development as well as advanced buffer management strategies. Currently he is working on innovating and developing connected integrated processes and was a lead scientist in the development of Fujifilm’s integrated continuous production system (MaruXTM) and co-inventor of the award winning SymphonXTM purification skid. Prior to joining FDB, Tibor’s previous experience included over 15 years academic experience in molecular biology/biochemistry.
Dr Charles Heise, Senior Staff Scientist, Bioprocess Strategy and Development, FUJIFILM Diosynth Biotechnologies.
Charlie Heise is a Senior Staff Scientist in the Bioprocessing Strategy & Development group at FUJIFILM Diosynth Biotechnologies (FDB). He joined the process development team at FDB’s Billingham, UK site in 2007 and has been technical lead on several programmes for manufacturing clinical and commercial biologics before becoming the site technical expert in cell harvest and filtration. Most recently he has developed and patented new approaches to downstream processing and has co-authored BioPhorum’s continuous processing publications. He is co-inventor of the award winning SymphonXTM purification skid and the downstream technical lead for FDB’s continuous biomanufacturing process (MaruXTM). Charlie gained his PhD in biophysical characterisation of a recombinant plant protein from the Biology Department, University of York.